A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine
Recruiting in Palo Alto (17 mi)
+1 other location
Overseen ByBrenda L Coleman, PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Brenda Coleman
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?The investigators hypothesize that people working in an acute care hospital setting will be able to successfully self-administer the intradermal vaccine (Intanza) in less time than nurse-administration of the regular intramuscular influenza vaccine (Vaxigrip). The investigators also hypothesize that people administering the intradermal vaccine for the second time will take less time to successfully administer than people administering it for the first time.
Eligibility Criteria
Inclusion Criteria
Work in any capacity (including physicians and midwives with admitting privileges), volunteer, or student at participating hospital
Able to read, understand, and respond to questionnaires
Able to read, understand, and sign an informed consent form
+3 more
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Self-administered intradermalExperimental Treatment1 Intervention
Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
Group II: Nurse-administered IMExperimental Treatment1 Intervention
Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
Group III: Repeat self-administration intradermalActive Control1 Intervention
Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Center for VaccinologyHalifax, Canada
Mount Sinai HospitalToronto, Canada
Loading ...
Who Is Running the Clinical Trial?
Brenda ColemanLead Sponsor
Sanofi Pasteur, a Sanofi CompanyIndustry Sponsor